肺癌组织中Atonal homolog 1与Disabled-2的表达及其临床意义

Ex pressions and significances of Atonal homolog 1 and Disabled-2 in lung cancer tissues

目的:分析Atonal homolog 1(Atoh1)和Disabled-2(Dab2)在肺癌组织中的表达及其与临床病理因素间的关系。方法:采用免疫组化方法检测Atoh1和Dab2在100例非小细胞肺癌中的表达情况。结果:在100例非小细胞肺癌中,Atoh1的细胞质和细胞核的平均阳性表达率分别为82.70%±19.06%和43.10%±27.16%,明显高于Atoh1在癌旁正常组织中的细胞质和细胞核的平均阳性表达率(71.80%±19.14%,18.77%±10.54%)。Atoh1在细胞核内的表达与肺癌的低分化(P=0.026)负相关,并且在肺腺癌(P=0.002)和女性患者(P=0.042)中阳性率较高。Dab2在细胞核内的表达与肺癌的原发灶T分期负相关(P=0.025),并且与肺癌的TNM分期相关(P=0.002)。Atoh1在肺癌中的细胞质表达与Dab2的细胞质表达显著相关(P<0.001)。结论:Atoh1在细胞核内的表达与肺癌的低分化负相关,Dab2在细胞核内的表达与肺癌患者TNM分期负相关。Atoh1和Dab2在肺癌组织中可能具有协同表达的现象。

Objective：To investigate the expression and correlation of Atonal homolog 1 （Atohl）and Disabled -2 （Dab2） in lung cancers, and analyze their relationships with the clinicalpathological parameters of lung squamous cell carcinoma and adenocarcinomas. Methods ： The expression patterns and levels of Atohl and Dab2 were examined using immunohistochemistry in 118 lung squamous ceils carcinoma and adenocarcinoma tissue samples. Results： The average cytoplasmic and nuclear positive rates of Atohl were increased significantly in lung cancers （82.70% 1,2 19.06% and 43.10% 1,2 27.16% ） than those in normal lung tissues （71.80% 1,2 19.14% and 18.77% 1,2 10.54% ）. The nu- clear expression of Atohl was negatively correlated with the poor differentiation （P = 0. 026 ）. And the nuclearexpression of Atohl was also correlated with the female gender of the patients （P =0. 042） and the adenocarcinoma histological type （P = 0. 002） of the lung cancer samples. Meanwhile, the nuclear expression of Dab2 was negatively correlated with primary tumor stage （P =0. 025 ） and TNM stage （P = 0.002）. We found that the cytoplasmic expres- sion of Atohl was correlated with the cytoplasmic expression of Dab2 （ P 〈 0. 001 ）. Conclusion： The nuclear expres- sion of Atohl was negatively correlated with poor differentiation. The nuclear expression of Dab2 was negatively corre- lated with TNM stage. Atohl may concurrently express with Dab2 in lung cancers.